SUPPORT GUIDE RESOURCES CD DOSING CS DOSING ORDERING BILLING AND INFORMATION GET CONNECTED AND INDICATIONS



MY PRACTICE. MY PATIENTS. MYOBLOC.

MYOBLOC® SUPPORT GUIDE

FOR PROVIDERS CARING FOR ADULTS WITH CERVICAL DYSTONIA OR CHRONIC SIALORRHEA



INDICATIONS

MYOBLOC® injection is indicated for:

- the treatment of cervical dystonia (CD) to reduce the severity of abnormal head position and neck pain associated with CD in adults
- the treatment of chronic sialorrhea in adults


Please refer to the full <u>Prescribing Information</u>, including <u>Boxed WARNING</u>, and additional Important Safety Information throughout and on page <u>7</u>.

WARNING DISTANT CRREAD OF TOVIN FEFECT

WARNING: DISTANT SPREAD OF TOXIN EFFECT

See full prescribing information for complete boxed WARNING.

The effects of MYOBLOC® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have an underlying condition that would predispose them to these symptoms.





MY GOAL: Relief for my patients.

Not actual patients.



TABLE OF CONTENTS

RESOURCES	02	
DOSING GUIDE FOR CERVICAL DYSTONIA		
DOSING GUIDE FOR CHRONIC SIALORRHEA	04	
ORDERING	05	
BILLING INFORMATION	06	
CIRCLE OF CARE™ PORTAL	06	
REIMBURSEMENT SUPPORT SERVICES		
IMPORTANT SAFETY INFORMATION AND INDICATIONS		

Please refer to the full <u>Prescribing Information</u>, including <u>Boxed WARNING</u>, and additional Important Safety Information throughout and on page <u>7</u>.

RESOURCES

BECOME A MYOBLOC PREMIER PARTNER

Explore the exclusive community designed for providers who administer MYOBLOC to their adult patients for the management of cervical dystonia & chronic sialorrhea.

- Take advantage of volume-based pricing on your MYOBLOC orders
- Perfect and practice your injection technique with MYLES, our interactive injection simulator
- Get answers to questions on dosing and administration
- Get help with billing, coding, and reimbursement



GET THE SUPPORT YOU NEED TO HELP YOUR PATIENTS

Our resources library features the tools you'll need to help you make MYOBLOC an important part of your treatment plan.


- Explore some of the patient profile types who might be appropriate candidates for MYOBLOC
- Reference digital guides to help you perform successful injections
- Gain important co-pay information to pass along to your patients
- Learn the best ways to integrate MYOBLOC into your practice



IMPORTANT SAFETY INFORMATION (CONT'D) CONTRAINDICATIONS

MYOBLOC is contraindicated in patients with:

- A known hypersensitivity to any botulinum toxin product or to any of the components in the formulation
- Infection at the proposed injection site(s)




MY GOAL: Relief for my patients.

Not actual patients.



DOSING GUIDE FOR CERVICAL DYSTONIA



DOSING RECOMMENDATIONS¹:


- The recommended initial total dose of MYOBLOC for patients with a prior history of tolerating botulinum toxin injections is 2,500 to 5,000 Units, divided among affected muscles
- Patients without a prior history of tolerating botulinum toxin injections should receive a lower initial dose
- Subsequent dosing should be determined by the patient's individual response

DOSING CONSIDERATIONS¹:

- Patient weight and muscle bulk
- Cervical dystonia symptom severity
- Risk of swallowing or breathing difficulties in patients with neuromuscular disorders¹
- Reduction of dosage is called for in patients with smaller neck muscles and who require bilateral injections into the sternocleidomastoid
- The duration of effect has been observed in studies to be between 12 and 16 weeks at doses of 5,000 Units or 10,000 Units¹

DOSING IS BASED ON CLINICAL TRIALS

TOTAL DOSE DIVIDED AMONG 2 TO 4 AFFECTED MUSCLES¹



AND INDICATIONS

Muscle	Starting Dose Range	Undiluted Volume
LEVATOR SCAPULAE	1,000 – 2,500 Units	0.2 - 0.5 mL
SCALENE COMPLEX	500 – 1,000 Units	0.1 - 0.2 mL
SEMISPINALIS CAPITIS	1,000 – 2,500 Units	0.2 - 0.5 mL
SPLENIUS CAPITIS	1,000 – 2,500 Units	0.2 - 0.5 mL
STERNOCLEIDOMASTOID	1,000 – 2,500 Units	0.2 - 0.5 mL
TRAPEZIUS	1,000 - 2,500 Units	0.2 - 0.5 mL



IMPORTANT SAFETY INFORMATION (cont'd) WARNINGS AND PRECAUTIONS

Lack of Interchangeability Between Botulinum Toxin Products

The potency units of MYOBLOC are specific to the preparation and biological activity assay method utilized. Due to differences in the aspects of this assay such as the vehicle, dilution scheme, and laboratory protocols for various potency assays, potency units are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of MYOBLOC cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method.

Please refer to the full <u>Prescribing Information</u>, including <u>Boxed WARNING</u>, and additional Important Safety Information throughout and on page <u>7</u>.








AND INDICATIONS

DOSING GUIDE FOR CHRONIC SIALORRHEA




DOSING RECOMMENDATIONS¹:

- Subsequent dosing and frequency of dosing should be optimized according to the patient's individual response
 - Generally, no more frequent than every 12 weeks
 - Individual patient responses may vary

DOSING CONSIDERATIONS¹:

- Sialorrhea symptom severity
- Risk of swallowing or breathing difficulties in patients with neuromuscular disorders



Gland	Starting Dose Range (units)	Undiluted Volume (mL)
Parotid	500 - 1,500	0.1 - 0.3
Injection Site 1	per gland	per gland
Submandibular	250	0.05
Injection Site 2	per gland	per gland




IMPORTANT SAFETY INFORMATION (cont'd) WARNINGS AND PRECAUTIONS (cont'd)

Hypersensitivity Reactions

Serious hypersensitivity reactions have been reported with botulinum toxin products. Angioedema, urticaria, and rash have occurred with MYOBLOC treatment. Hypersensitivity reactions can also include anaphylaxis, serum sickness, soft tissue edema, and dyspnea. If serious and/or immediate hypersensitivity reactions occur, discontinue further injection of MYOBLOC and institute appropriate medical therapy immediately. The use of MYOBLOC in patients with a known hypersensitivity to any botulinum neurotoxin or to any of the excipients (human albumin, sucrose), could lead to a life-threatening allergic reaction.





MY EXPECTATION: Assistance with ordering.

Not actual patients.



AVAILABLE ORDERING OPTIONS

Ordering MYOBLOC for your patients is easy. MYOBLOC is available in 3 vial sizes for dosing flexibility.¹ **MYOBLOC is ready to use and requires no mixing.**

AVAILABLE MYOBLOC VIAL SIZES



2,500 Units/0.5 mL NDC# 10454-710-10*



5,000 Units/1 mL NDC# 10454-711-10*



10,000 Units/2 mL NDC# 10454-712-10*

MYOBLOC IS:

- Delivered the next day if a phone order is received by 5:00 pm, Eastern Time[†]
- Packaged to maintain the required temperature between 36-46 °F (2-8 °C) during shipment. MYOBLOC must be refrigerated
- A ready-to-use liquid formulation that does not require reconstitution
- DO NOT FREEZE OR SHAKE

Take advantage of volume-based discounts and get current pricing information on the Premier Partner page

Please note that for billing purposes, some payers may require an 11-digit code based on the NDC number. Therefore, a zero must be entered into the sixth position (example: "10454-0710-10"). This is consistent with the Red Book and First Databank listings. Prices listed are updated as of [April 24, 2023], and are subject to change without notice.

†Orders received on Friday are shipped the following Monday. MYOBLOC is not returnable for credit under any condition, including drug that has been mishandled or has expired. For assistance with disposal of expired drug, please contact Solstice Neurosciences, LLC, at <u>1-888-461-2255</u>. For all other product-related issues, please contact Solstice Neurosciences, LLC, at <u>1-888-461-2255</u> within 30 days of purchase. Payment terms for MYOBLOC are net 90 days. See Terms and Conditions for further details about ordering MYOBLOC by visiting MYOBLOChcp.com and accessing the Ordering link.

Please refer to the full <u>Prescribing Information</u>, including <u>Boxed WARNING</u>, and additional Important Safety Information throughout and on page <u>7</u>.

HOW TO ORDER





Call 1-888-461-2255

MYOBLOC Premier Partners can enjoy special access to our volume-based pricing model.

The more MYOBLOC you order, the more you save. Ask about it today.



AND INDICATIONS

Email your order to GMB-SPS-SOLSTICE@cordlogistics.com

Include your name, your MYOBLOC account number, the number of vials and vial sizes you would like, and where you would like them shipped. Our team will reach out to confirm your order.

IMPORTANT SAFETY INFORMATION (cont'd) WARNINGS AND PRECAUTIONS (cont'd)

Dysphagia and Breathing Difficulties

Treatment with MYOBLOC and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or swallowing. When distant effects occur, additional respiratory muscles may be involved. Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several months and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised.



MY RESOURCES: Accessible billing and reimbursement support. Not actual patient.

MYOBLOC® rimabotulinumtoxinB

CIRCLE OF CARE™ PORTAL

HOW WE ARE MAKING REIMBURSEMENT EASY FOR YOU AND YOUR STAFF

- Each practice is assigned a Circle of Care™ Case Manager who assists in the benefit investigation, prior authorization, specialty pharmacy communication, and/or Patient Assistance Program application for MYOBLOC
- Online submission for insurance benefit investigations and prior authorizations for new and current MYOBLOC patients
- 2-business day turnaround for most benefit investigations
- Prior authorization assistance, if required
- Real-time patient status updates



REIMBURSEMENT SUPPORT SERVICES



MYOBLOC CIRCLE OF CARE™ SPECIALISTS

 Provide information, as requested by the healthcare provider, on topics such as patient support services and insurance benefits



MYOBLOC CIRCLE OF CARE™ PORTAL

• Online submission for insurance benefit investigations and prior authorization facilitation for new and current MYOBLOC patients



REGIONAL REIMBURSEMENT SPECIALIST

 Provides information, as requested by the healthcare provider, on topics such as billing, coding, and reimbursement, as well as insurance and government guidelines/policies

Please refer to the full <u>Prescribing Information</u>, including <u>Boxed WARNING</u>, and additional Important Safety Information throughout and on page <u>7</u>.

REIMBURSEMENT SUPPORT SERVICES (cont'd)

Condition	Code	Description	
ICD10 - G24.3 CPT - 64616 Cervical dystonia‡ 95873	ICD10 - G24.3	Spasmodic torticollis (CD)	
	CPT - 64616	Chemodenervation of muscle(s), cervical spinal muscle(s); 50 modifier for bilateral injections	
	J0587	MYOBLOC is billed in 100 units (ie, 5,000 units = 50 units billed)	
	Electrical stimulation for guidance in conjunction with chemodenervation		
	95874	Needle electromyography for guidance in conjunction with chemodenervation	
	76942	Ultrasonic guidance for needle placement imaging	
	ICD10 - K11.7	Disturbances of salivary secretion (sialorrhea)	
Chronic	CPT - 64611	Chemodenervation of parotid and submandibular salivary glands, bilateral	
sialorrhea [‡]	ialorrhea‡ J0587	MYOBLOC is billed in 100 units (ie, 5,000 units = 50 units billed)	
	76942	Ultrasonic guidance for needle placement imaging	

For more information on reimbursement for MYOBLOC, including billing and coding, <u>visit our Reimbursement page</u>

AND INDICATIONS

Request a Reimbursement Specialist



*Please note that for billing purposes, some payers may require an 11-digit code based on the NDC number. Therefore, a zero must be entered into the sixth position (example: "10454-0710-10"). This is consistent with the Red Book and First Databank listings. Prices listed are updated, and are subject to change without notice.

[†]Orders received on Friday are shipped the following Monday. MYOBLOC is not returnable for credit under any condition, including drug that has been mishandled or has expired. For assistance with disposal of expired drug, please contact Solstice Neurosciences, LLC, at <u>1-888-461-2255</u>. For all other product-related issues, please contact Solstice Neurosciences, LLC, at <u>1-888-461-2255</u> within 30 days of purchase. Payment terms for MYOBLOC are net 90 days. See Terms and Conditions for further details about ordering MYOBLOC by visiting MYOBLOChcp.com and accessing the Ordering link.

[‡]Table contains possible appropriate codes for cervical dystonia and chronic sialorrhea.

IMPORTANT SAFETY INFORMATION (cont'd) WARNINGS AND PRECAUTIONS (cont'd)

- Dysphagia and Breathing Difficulties (cont'd)
- Cervical Dystonia: Treatment of cervical dystonia with botulinum toxins may weaken neck muscles that serve as accessory muscles of ventilation. This may result in a critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these accessory muscles. There have been postmarketing reports of serious breathing difficulties, including respiratory failure, in cervical dystonia patients. Patients treated with botulinum toxin may require immediate medical attention should they develop problems with swallowing, speech or respiratory disorders. These reactions can occur within hours to weeks after injection with botulinum toxin.

SUPPORT GUIDE RESOURCES CD DOSING CS DOSING ORDERING BILLING AND REIMBURSEMENT IMPORTANT SAFETY ORDERING AND INFORMATION GET CONNECTED AND INDICATIONS

IMPORTANT SAFETY INFORMATION

WARNING: DISTANT SPREAD OF TOXIN EFFECT

See full prescribing information for complete boxed WARNING.

The effects of MYOBLOC® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have an underlying condition that would predispose them to these symptoms.

CONTRAINDICATIONS

MYOBLOC is contraindicated in patients with:

- A known hypersensitivity to any botulinum toxin product or to any of the components in the formulation
- Infection at the proposed injection site(s)

WARNINGS AND PRECAUTIONS

Lack of Interchangeability Between Botulinum Toxin Products

The potency units of MYOBLOC are specific to the preparation and biological activity assay method utilized. Due to differences in the aspects of this assay such as the vehicle, dilution scheme, and laboratory protocols for various potency assays, potency units are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of MYOBLOC cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method.

Hypersensitivity Reactions

Serious hypersensitivity reactions have been reported with botulinum toxin products. Angioedema, urticaria, and rash have occurred with MYOBLOC treatment. Hypersensitivity reactions can also include anaphylaxis, serum sickness, soft tissue edema, and dyspnea. If serious and/or immediate hypersensitivity reactions occur, discontinue further injection of MYOBLOC and institute appropriate medical therapy immediately. The use of MYOBLOC in patients with a known hypersensitivity to any botulinum neurotoxin or to any of the excipients (human albumin, sucrose), could lead to a life-threatening allergic reaction.

Dysphagia and Breathing Difficulties

Treatment with MYOBLOC and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or swallowing. When distant effects occur, additional respiratory muscles may be involved. Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several months and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised.

Cervical Dystonia: Treatment of cervical dystonia with botulinum toxins may weaken neck muscles that serve as accessory
muscles of ventilation. This may result in a critical loss of breathing capacity in patients with respiratory disorders who
may have become dependent upon these accessory muscles. There have been postmarketing reports of serious breathing

difficulties, including respiratory failure, in cervical dystonia patients. Patients treated with botulinum toxin may require immediate medical attention should they develop problems with swallowing, speech or respiratory disorders. These reactions can occur within hours to weeks after injection with botulinum toxin.

- Pre-Existing Neuromuscular Disorders: Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis,
 or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly
 closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant
 effects including severe dysphagia and respiratory compromise from typical doses of MYOBLOC.
- Human Albumin and Transmission of Viral Diseases

This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would be considered extremely remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

MOST COMMON ADVERSE REACTIONS (>5% of patients and >5% more than placebo)

Cervical Dystonia: dry mouth, dysphagia, injection site pain, headache

Chronic Sialorrhea: dry mouth, dysphagia

DRUG INTERACTIONS

Aminoglycosides and Other Agents Interfering with Neuromuscular Transmission: Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated. Anticholinergic Drugs: Use of anticholinergic drugs after administration of MYOBLOC may potentiate systemic anticholinergic effects. Other Botulinum Neurotoxin Products: The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. Muscle Relaxants: Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of MYOBLOC.

INDICATIONS

MYOBLOC® injection is indicated for:

- the treatment of cervical dystonia (CD) to reduce the severity of abnormal head position and neck pain associated with CD in adults
- the treatment of chronic sialorrhea in adults

Please refer to the full <u>Prescribing Information</u>, including <u>Boxed WARNING</u>.

REFERENCES: 1. MYOBLOC® US Prescribing Information. Solstice Neurosciences, LLC.



MY TRAINING.
MY SUPPORT.
MYOBLOC.

Become a MYOBLOC Premier Partner

to access exclusive content and support including volume-based discounts, expert injection training, and more.





MY ORDER starts here.

Call <u>1-888-461-2255</u> or email

GMB-SPS-SOLSTICE@cordlogistics.com.



For reimbursement support, including billing and coding, visit the Reimbursement Support page

INDICATIONS

MYOBLOC® injection is indicated for:

- the treatment of cervical dystonia (CD) to reduce the severity of abnormal head position and neck pain associated with CD in adults
- the treatment of chronic sialorrhea in adults

Please refer to the full <u>Prescribing Information</u>, including <u>Boxed WARNING</u>, and additional Important Safety Information on page <u>7</u>.

IMPORTANT SAFETY INFORMATION

WARNING: DISTANT SPREAD OF TOXIN EFFECT

See full prescribing information for complete boxed WARNING.

The effects of MYOBLOC® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have an underlying condition that would predispose them to these symptoms.



